109048 ⎘
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor; Recombinant DNA-technology; DNA or RNA fragments; Modified forms thereof Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
PEPTIDE-BINDING HYBRID LIPOSOME EXOSOME, PEPTIDE-BINDING EXOSOME, COMPOSITION CONTAINING SAME, AND METHOD OF FORMING SAME
#1202COMPOSITIONS AND METHODS OF ALLEVIATING RESISTANCE TO CHEMOTHERAPY
#1203PHOTO-CROSSLINKED BIOREDUCIBLE POLYMERIC NANOPARTICLES FOR ENHANCED RNA DELIVERY
#1204METHODS FOR TREATMENT RESPONSE TO CANCERS
#1205METHOD FOR MEASURING SOMATIC DNA MUTATION AND DNA DAMAGE PROFILES AND A DIAGNOSTIC KIT SUITABLE THEREFORE
#1206METHOD OF MODULATING THE EXTENT OF GALACTOSYLATION OF PROTEINS IN MAMMALIAN PRODUCER CELLS
#1207METHOD OF TREATMENT FOR OPTIC ATROPHY
#1208COMPOSITION FOR DIAGNOSIS, PREVENTION, OR TREATMENT OF VASCULAR SMOOTH MUSCLE CELL PROLIFERATIVE DISEASE, USING MIRNA INHIBITOR
#1209MOLECULAR THERAPEUTICS FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY AND HEART FAILURE ASSOCIATED WITH MYBPC3 GENE MUTATIONS
#1210NUCLEIC ACID AGENTS FOR TREATMENT OF NON-SMALL-CELL LUNG CANCER
#1211NUCLEIC ACIDS CONTAINING ABASIC NUCLEOSIDES
#1212COMPOSITIONS AND METHODS FOR THE TREATMENT OF PCDH19 RELATED DISORDERS
#1213Engineered Exosome for Treating Hypertrophic Scar (Hts), and Preparation Method and Use Thereof
#1214TREATMENT OF COMPLEMENT-MEDIATED DISORDERS
#1215COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES CONTAINING A miRNA INHIBITOR AND USE THEREOF
#1216COMPOSITIONS AND METHODS FOR INHIBITING COMPLEMENT COMPONENT 3 EXPRESSION
#1217Composition for inducing direct reprogramming comprising self-assembled RNA construct
#1218BAG3 COMPOSITIONS AND METHODS
#1219BLOCK COPOLYMERS AND USES THEREOF
#1220Lipid nanoparticle compositions and uses thereof
#1221Uses of Inhibitors of YTH Domain Family Proteins in the Management of Cognitive or Developmental Disorders
#1222NANOMATERIALS
#1223POLY-GA PROTEINS IN ALZHEIMER’S DISEASE
#1224PLANT REGULATORY ELEMENTS AND USES THEREOF
#1225GENE KNOCKOUT OF NRF2 FOR TREATMENT OF CANCER
#1226Means and Methods for Chronic Wound Healing
#1227Compositions and Methods for Treating Cag Repeat Diseases
#1228NUCLEIC ACID-CONTROLLED CATALYTIC RNAS FOR TRIGGER-RESPONSIVE REGULATION
#1229KISSPEPTIN 1 (KISS1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1230MODIFIED SMALL INTERFERING RNA MOLECULES WITH REDUCED OFF-TARGET EFFECTS
#1231COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING LIVER FIBROSIS
#1232PEPTIDE HAVING INDEPENDENTLY STABILIZED HYDROPHOBIC ALPHA HELIX, PEPTIDE COMPLEX COMPRISING SAME AND USES THEREOF
#1233TARGETING NANOPARTICLES FOR THERAPY
#1234NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS
#1235Peptides for Anti Fibrotic Therapy
#1236COMPOSITION FOR TREATING MUSCLE LOSS-RELATED DISEASES COMPRISING EXOSOMES DERIVED FROM TONSIL MESENCHYMAL STEM CELLS
#1237METHODS AND COMPOSITIONS FOR TARGETING SV2 PROTEINS FOR IMMUNE REGULATION
#1238Methods and Compositions for RNA-Directed Target DNA Modification and For RNA-Directed Modulation of Transcription
#1239GENE KNOCKOUT OF NRF2 FOR TREATMENT OF CANCER
#1240GENE KNOCKOUT OF NRF2 FOR TREATMENT OF CANCER
#1241METHODS OF MODULATING RNA TRANSLATION
#1242THERAPEUTIC TREATMENT FOR FRAGILE X-ASSOCIATED DISORDER
#1243FOLDING OLIGONUCLEOTIDES
#1244ANTAGONIST OF THE MIRNA-106B-5P TO TREAT OR PREVENT THE CARDIOTOXICITY THAT IS DEVELOPED IN ONCOLOGIC PATIENTS AFTER RECEIVING ANTHRACYCLINE-BASED CHEMOTHERAPY
#1245miRNA REPROGRAMMING OF SMOOTH MUSCLE CELLS INTO ENDOTHELIAL CELLS
#1246OLIGONUCLEOTIDES FOR TARGETING COMPLEMENT C5
#1247AN ANTI-INFLAMMATORY COMPOSITION AND A METHOD OF OBTAINING THE SAME
#1248OLIGONUCLEOTIDES FOR TISSUE SPECIFIC GENE EXPRESSION MODULATION
#1249COMPOSITIONS AND METHODS FOR IMMUNOONCOLOGY
#1250COMPOSITIONS AND METHODS FOR SKIPPING EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY
#1251GENE EDITING FOR HEMOPHILIA A WITH IMPROVED FACTOR VIII EXPRESSION
#1252COMPOSITIONS AND METHODS FOR TREATING HUNTINGTON'S DISEASE
#1253POLYMER NANOPARTICLE AND DNA NANOSTRUCTURE COMPOSITIONS AND METHODS FOR NON-VIRAL DELIVERY
#1254ANTISENSE-INDUCED EXON EXCLUSION IN TYPE VII COLLAGEN
#1255METHOD OF TREATING PANCREATIC CANCER
#1256SYSTEMS AND METHODS FOR DETERMINING EFFECTS OF THERAPIES AND GENETIC VARIATION ON POLYADENYLATION SITE SELECTION
#1257METHODS AND COMPOSITIONS FOR GENOME EDITING
#1258MODIFIED DOUBLE-STRANDED RNA AGENTS
#1259BIOACTIVE RENAL CELLS
#1260MODIFIED AAV CONSTRUCTS AND USES THEREOF
#1261COMBINATION OF OLIGONUCLEOTIDES FOR MODULATING RTEL1 AND FUBP1
#1262LIPOPHILIC SIRNA CONJUGATES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES
#1263RNAi TARGETING HNRNPH2 MISSENSE MUTATIONS FOR TREATMENT OF BAIN SYNDROME
#1264RNAi TARGETING KIF1A MISSENSE MUTATIONS FOR TREATMENT OF KIF1A ASSOCIATED NEUROLOGICAL DISORDER
#1265Atg8ylation coordinates stress granule formation and mTOR inactivation in response to lysosomal damage
#1266FOXO1-TARGETED THERAPY FOR THE TREATMENT OF CANCER
#1267CONDITION-ACTIVATABLE NUCLEIC ACID CONSTRUCTS AND THEIR USES FOR TREATING NEUROLOGICAL DISEASES
#1268CORRECTION OF SPLICING MUTATIONS CAUSING PRIMARY CILIARY DYSKINESIA USING OLIGONUCLEOTIDES
#1269COMPOSITIONS AND METHODS FOR MODULATING NLRP3 OR NLRP1 EXPRESSION
#1270MUC5B-TARGETED ANTISENSE OLIGONUCLEOTIDES AND RELATED METHODS FOR MODULATING MUCIN EXPRESSION
#1271TRANSTHYRETIN (TTR) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1272NOVEL RNA TRANSCRIPT
#1273INTEGRIN TARGETING LIGANDS FOR OCULAR DELIVERY OF RNAI COMPOUNDS
#1274PREVENTIVE OR THERAPEUTIC AGENT FOR BENIGN ADULT FAMILIAL MYOCLONIC EPILEPSY
#1275METHOD FOR ENHANCING THE SUSTAINED RELEASE ABILITY OF A NUCLEIC ACID DRUG
#1276NOVEL CRISPR-ASSOCIATED TRANSPOSON SYSTEMS AND COMPONENTS
#1277MODELS OF TAUOPATHY
#1278UFMYLATION INHIBITION TO TARGET TAUOPATHY IN HUMAN NEURONS
#1279METHODS AND PRODUCTS FOR GENETIC ENGINEERING
#1280POLYCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS
#1281PLAKOPHILIN-2 (PKP2) GENE THERAPY USING AAV VECTOR
#1282Muscle targeting complexes and uses thereof for treating dystrophinopathies
#1283CELL-DERIVED NANOVESICLES FOR IN VIVO TRANSPORT AND DELIVERY OF THERAPEUTIC MATERIALS
#1284Compositions and methods for inhibiting LPA expression
#1285UNC13A ANTISENSE OLIGONUCLEOTIDES
#1286Tuning cascade assay kinetics via molecular design
#1287Nucleic Acid Sponges
#1288ENGINEERED CIRCULAR RNA CIRCMIR-29B AND USE THEREOF IN PREPARATION OF MEDICINE FOR TREATING MUSCLE ATROPHY
#1289MICRORNA-541-3P AS A THERAPEUTIC AGENT AS WELL AS ZNF101 AND CASZ1 AS THERAPEUTIC TARGETS TO LOWER PLASMA LDL-C, INCREASE PLASMA HDL-C, AND REDUCE ATHEROSCLEROSIS
#1290TREM COMPOSITIONS AND METHODS OF USE
#1291PRODUCTS AND METHODS FOR MYELIN PROTEIN ZERO SILENCING AND TREATING CMT1B DISEASE
#1292ANGIOTENSINOGEN-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF
#1293EXPLOITING IL33 SECRETION AS A THERAPEUTIC TARGET IN CANCER
#1294PROGRAMMABLE CONDITIONAL SIRNAS AND USES THEREOF
#1295TUMOR DELIVERY OF DENDRITIC OLIGONUCLEOTIDES
#1296METHODS FOR IMPROVING RELAXATION OF STRIATED MYOCYTES
#1297IN VIVO DELIVERY OF OLIGONUCLEOTIDES
#1298Compounds and Methods for Reducing ATXN2 Expression
#1299COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
#1300AGENTS USEFUL IN TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
#1301THERAPEUTICS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
#1302SGF29 AS A TARGET FOR HOX/MYC DRIVEN CANCERS
#1303COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
#1304RNAi induced C9ORF72 suppression for the treatment of ALS/FTD
#1305Muscle targeting complexes and uses thereof for treating dystrophinopathies
#1306MANIPULATION OF THE RETINOIC ACID SIGNALING PATHWAY
#1307CATIONIC POLYMERS
#1308RNA TARGETING OF MUTATIONS VIA SUPPRESSOR tRNAs AND DEAMINASES
#1309NUCLEOTIDE AND USE THEREOF
#1310STAUFEN1 REGULATING AGENTS AND ASSOCIATED METHODS
#1311LIGAND CONJUGATES FOR DELIVERY OF THERAPEUTICALLY ACTIVE AGENTS
#1312Utilization of Micro-RNA for Downregulation of Cytotoxic Transgene Expression by Modified Vaccinia Virus Ankara (MVA)
#1313Site-Specific Crosslinking of Antibodies
#1314NKD2 AS TARGET FOR TREATING RENAL FIBROSIS
#1315BASE EDITING OF PCSK9 AND METHODS OF USING SAME FOR TREATMENT OF DISEASE
#1316PLAKOPHILIN-2 (PKP2) GENE THERAPY USING AAV VECTOR
#1317HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE-DRUG CONJUGATE
#1318Gene-regulating compositions and methods for improved immunotherapy
#1319MICRORNA-29 COMPOUNDS, COMPOSITIONS AND USES IN THERAPY
#1320PARTICLE-MEDIATED DELIVERY OF BIOLOGICS
#1321COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS
#1322COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS
#1323INHIBITOR OLIGONUCLEOTIDES AND METHODS OF USE THEREOF
#1324METHODS AND COMPOSITIONS FOR TREATING A PREMATURE TERMINATION CODON-MEDIATED DISORDER
#1325GENE THERAPY CONSTRUCT FOR TREATING POMPE DISEASE, PHARMACEUTICAL COMPOSITION, AND METHOD
#1326ANGPTL4 OLIGONUCLEOTIDES INFLUENCING THE REGULATION OF THE FATTY ACID METABOLISM
#1327TARGETED GENE THERAPY FOR DM-1 MYOTONIC DYSTROPHY
#1328NUCLEIC ACID MOLECULE AND ITS USE
#1329METHOD FOR TREATING A DISEASE
#1330Method For Promoting Differentiation Of Pluripotent Stem Cells By Reducing Undifferentiated State Thereof
#1331MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES
#1332MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR MODULATION OF GENES ASSOCIATED WITH MUSCLE HEALTH
#1333DNAZYME HYDROGEL FORMULATIONS
#1334RNA binding and stabilising cationic liposome, its application and method of loading the liposome with emetine
#1335LIPOSOMAL PARTICLES, METHODS OF MAKING SAME AND USES THEREOF
#1336HYBRID NUCLEIC ACID SEQUENCES FOR GENOME ENGINEERING
#1337Antisense Oligonucleotide (ASO) Gene Inhibition and Treatment
#1338ANTISENSE OLIGONUCLEOTIDES FOR MODULATING TMEM106B EXPRESSION
#1339ANTISENSE COMPOUND FOR MODULATING WFDC2 EXPRESSION
#1340Conditional Double Stranded Antisense Oligonucleotides
#1341Treatment of Liver Diseases With Cell Death Inducing DFFA Like Effector B (CIDEB) Inhibitors
#1342PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING COLON CANCER INCLUDING EXTRACELLULAR VESICLES LOADED WITH MACC1 INHIBITOR AS ACTIVE INGREDIENT
#1343COMPOUNDS AND METHODS FOR MODULATING HUNTINGTIN
#1344ENGINEERED CLASS 2 TYPE V CRISPR SYSTEMS
#1345Compound, a conjugate and uses thereof
#1346FUSION PROTEIN BETWEEN SHORT FORM ROD-DERIVED CONE VIABILITY FACTOR AND A HYDROPHILIC PEPTIDE
#1347COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS
#1348COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS
#1349COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS
#1350COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS
#1351INTEGRATED ELECTROCHEMICAL APTASENSORS FOR MEASURING CELL DEATH AND CYTOKINE ACTIVITY FROM INTACT TISSUE SAMPLES
#1352INCLUSION BODY MEDIATED METHOD FOR DOUBLE-STRANDED RNA PRODUCING
#1353METHODS AND COMPOSITIONS FOR PREPARING TAGATOSE FROM FRUCTOSE
#1354TARGETED GENE EDITING PLATFORM INDEPENDENT OF DNA DOUBLE STRAND BREAK AND USES THEREOF
#1355PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING CD300C EXPRESSION INHIBITOR OR ACTIVITY INHIBITOR
#1356ANTI-TRANSFERRIN RECEPTOR ANTIBODY-PMO CONJUGATES FOR INDUCING DMD EXON 44 SKIPPING
#1357Antisense Nucleic Acids
#1358DYSTROPHIN EXON SKIPPING OLIGONUCLEOTIDES
#1359POLYMERIC NANOPARTICLE DRUG DELIVERY SYSTEM
#1360HUNTINGTIN (HTT) IRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
#1361GAPMER OLIGONUCLEOTIDES COMPRISING A PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGE
#1362Selective Antisense Compounds and Uses Thereof
#1363OLIGOMERIC COMPOUND FOR DYSTROPHIN RESCUE IN DMD PATIENTS THROUGHOUT SKIPPING OF EXON-51
#1364MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES
#1365NOVEL COMPOSITIONS FOR NEUROPROTECTION AND AXON REGENERATION
#1366DENDRITIC CONJUGATES FOR THE LUNG DELIVERY OF THERAPEUTIC OLIGONUCLEOTIDES
#1367COMPOSITIONS AND METHODS FOR CONTROLLING INSECTS
#1368CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING BETA HEMOGLOBINOPATHIES
#1369METHODS AND MEANS FOR EFFICIENT SKIPPING OF AT LEAST ONE OF THE FOLLOWING EXONS OF THE HUMAN DUCHENNE MUSCULAR DYSTROPHY GENE: 43, 46, 50-53
#1370MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS
#1371ANTISENSE OLIGONUCLEOTIDE THERAPY FOR H3.3 K27M DIFFUSE MIDLINE GLIOMAS
#1372COMPOUNDS AND METHODS FOR MODULATING SCN1A EXPRESSION
#1373LINKAGE MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF
#1374COMPOUNDS TARGETING PMP22 FOR THE TREATMENT OF CHARCOT-MARIE-TOOTH DISEASE
#1375MICRORNA-29 COMPOUNDS, COMPOSITIONS AND USES IN THERAPY, AND METHODS FOR EVALUATING TENDINOPATHIC LESIONS
#1376CANCER TREATMENT USING siRNA TO MODULATE EXPRESSION OF PRDM2/RIZ PROTEIN
#1377DENDRITIC CONJUGATES FOR THE BRAIN DELIVERY OF THERAPEUTIC OLIGONUCLEOTIDES
#1378NUCLEIC ACID MOLECULE AND USE OF THE NUCLEIC ACID MOLECULE IN THERAPY OF DISEASES INDUCED BY EXPANSION OF TRINUCLEOTIDE CAG REPEATS
#1379COMPOSITIONS AND METHODS FOR MODULATING GENE TRANSCRIPTION NETWORKS
#1380METHOD FOR PRODUCING HIGHLY PROLIFERATIVE CELL, AND HIGHLY PROLIFERATIVE CELL AND USE THEREOF
#1381MULTIGENE CONSTRUCTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER COMPLEMENT DYSREGULATION-RELATED CONDITIONS
#1382COMPOSITIONS AND METHODS FOR INTRACELLULAR THERAPEUTICS
#1383COMPOSITION AND METHOD TO TREAT CACHEXIA
#1384NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING
#1385High Efficiency Beef Cattle Having Modified ACTN3 Genes
#1386APTAMER-siRNA FUSIONS
#1387RNA TARGETING OF MUTATIONS VIA SUPPRESSOR tRNAs AND DEAMINASES
#1388RESTORATION OF THE CFTR FUNCTION BY SPLICING MODULATION
#1389SNRNA TARGETING USH2A PRE-MRNA AND APPLICATION THEREOF
#1390COMPOSITIONS AND METHODS FOR SIRNA TREATMENT OF MUSCULAR DYSTROPHY
#1391DOUBLE STRANDED NUCLEIC ACID COMPOUNDS INHIBITING ZPI
#1392CONTROL OF INSECT INFESTATION
#1393COMPOSITIONS AND METHODS FOR TREATING SICKLE CELL DISEASES
#1394Compositions and methods for modulating apolipoprotein (a) expression
#1395MULTI-EFFECTOR CRISPR BASED DIAGNOSTIC SYSTEMS
#1396THREE-DIMENSIONAL DIRECT NEURONAL REPROGRAMMING TO MODEL ALZHEIMER'S DISEASE IN HUMAN NEURONS
#1397COSTIMULATORY B7-H1 IN RENAL CELL CARCINOMA PATIENTS: INDICATOR OF TUMOR AGGRESSIVENESS AND POTENTIAL THERAPEUTIC TARGET
#1398PHARMACEUTICAL COMPOSITIONS TARGETING IMMUNE-MEDIATED PROCESSES IN NEURODEGENERATIVE DISEASE
#1399METHODS FOR TREATMENT OF NEURON DEGENERATION
#1400Cationic Polymeric Nanoparticles and Their Uses in Treating Diseases
#1401ROTATIONALLY SEQUESTERED TRANSLATORS
#1402DUAL FUNCTION HYBRID NANOPARTICLES AND METHODS OF USING THE SAME TO TREAT DISEASES AND DISORDERS
#1403EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY
#1404BETA-CATENIN (CTNNB1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1405METHOD
#1406GUANINE-RICH DEOXYRIBOZYMES, COMPOSITIONS AND USES THEREOF
#1407COMPOSITIONS AND METHODS FOR INHIBITING LPA EXPRESSION
#1408METHODS OF SYNTHESIZING OLIGONUCLEOTIDES USING TETHERED NUCLEOTIDES
#1409ENZYMES WITH RUVC DOMAINS
#1410SPINK1 AS A TARGET FOR THERAPEUTIC INTERVENTION IN LUNG DISEASES
#1411METHODS FOR TREATING SICKLE CELL DISEASE OR BETA THALASSEMIA USING COMPLEMENT ALTERNATIVE PATHWAY INHIBITORS
#1412NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM
#1413A SHORTENED P63-PROTEIN DOMAIN TO ENHANCE HUMAN CARDIAC REPROGRAMMING
#1414OPTIMIZING T CELL DIFFERENTIATION STATE WITH MICRORNAS
#1415Compositions and Methods for Treatment and Prevention of Misfolded Proteins
#1416TREATMENT OF CANCERS OR NEOPLASMS BY INHIBITING KIF15
#1417CATIONIC LIPID, LIPOSOME CONTAINING CATIONIC LIPID, AND NUCLEIC-ACID PHARMACEUTICAL COMPOSITION CONTAINING LIPOSOME AND FORMULATION AND APPLICATION THEREOF
#1418SERUM CIRCRNA MARKER FOR RECOGNIZING CRANIOSYNOSTOSIS AND APPLICATION THEREOF
#1419CRISPR/CAS9-BASED COMPOSITIONS AND METHODS FOR TREATING RETINAL DEGENERATIONS
#1420THREOSE NUCLEIC ACID ANTISENSE OLIGONUCLEOTIDES AND METHODS THEREOF
#1421RNA EDITING
#1422METHODS OF CONTROLLING RNA BINDING PROTEIN ACTIVITY
#1423COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF TMIGD2
#1424SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES WITH INCREASED STABILITY
#1425COMPOUNDS AND METHODS FOR REDUCING DUX4 EXPRESSION
#14262'-MODIFIED NUCLEOSIDE BASED OLIGONUCLEOTIDE PRODRUGS
#1427MODIFIED PRODUCER CELLS FOR EXTRACELLULAR VESICLE PRODUCTION
#1428TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN IMMUNE MODULATORY AGENT RELEASED USING AN INGESTIBLE DEVICE
#1429COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF THERAPEUTIC AND/OR DIAGNOSTIC SPECIES
#1430PRODUCTS AND METHODS FOR PROMOTING MYOGENESIS
#1431A NON-CANONICAL SIGNALING ACTIVITY OF CGAMP TRIGGERS DNA DAMAGE RESPONSE SIGNALING
#1432ADENO-ASSOCIATED VIRUS COMPLEX WITH IMPROVED EXPRESSION OF RUNX3 GENE AND USES FOR PREVENTING OR TREATING KRAS MUTATED LUNG CANCER
#1433ANTISENSE OLIGONUCLEOTIDES TARGETING UNC13A
#1434ANTISENSE POLYNUCLEOTIDES TO INDUCE EXON SKIPPING AND METHOD OF TREATING DYSTROPHIES
#1435NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL
#1436GALNAC-MONOMERS AND GALNAC-NUCLEIC ACID CONJUGATES
#1437COMPOSITIONS COMPRISING DOPED SILICON PARTICLES, AND RELATED METHODS
#1438OLIGONUCLEOTIDE FOR INHIBITING QUAKING ACTIVITY
#1439NOVEL THERAPEUTIC DELIVERY MOIETIES AND USES THEREOF
#1440MODULATORS OF ENaC EXPRESSION
#1441OLIGONUCLEOTIDES TARGETING RNA BINDING PROTEIN SITES
#1442MODIFIED OLIGONUCLEOTIDES TARGETING SNPs
#1443METHODS FOR REACTIVATING GENES ON THE INACTIVE X CHROMOSOME
#1444LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SERUM AMYLOID A GENE
#1445Double-Stranded Nucleic Acid Molecule for Treating Proliferative Vitreoretinopathy and Use Thereof
#1446NUCLEIC ACID CONSTRUCT ENABLING EXPRESSION AND INHIBITION OF GENE SIMULTANEOUSLY
#1447COMPOSITIONS COMPRISING EXON SKIPPING OLIGONUCLEOTIDE CONJUGATES FOR TREATING MUSCULAR DYSTROPHY
#1448DISE-INDUCING SRNA-POLYPLEXES AND SRNA-LIPOPOLYPLEXES AND METHODS OF USING THE SAME TO TREAT CANCER
#1449CONJUGATE OF SAPONIN, OLIGONUCLEOTIDE AND GALNAC
#1450COMPOSITIONS AND METHODS FOR CELLULAR REPROGRAMMING USING CIRCULAR RNA
#1451STRUCTURE-BASED DESIGN OF ANTISENSE OLIGONUCLEOTIDE DRUGS
#1452BLOCK COPOLYMERS
#1453Therapeutic Compounds for Inhibiting and Reducing the Expression of Cell Surface Proteins
#1454TOPICAL DELIVERY OF THERAPEUTIC OLIGONUCLEOTIDES
#1455CELLULAR THERAPIES FOR CANCER BY INHIBITION OF MONOCARBOXYLATE TRANSPORTER 11
#1456MINOR SPLICEOSOME TARGETING COMPOSITIONS AND THEIR USE IN CANCER TREATMENT
#1457NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, AND PREPARATION METHOD AND USE
#1458TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
#1459LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERY OF MRNA AND LONG NUCLEIC ACIDS
#1460METHOD FOR RNAI FUNGICIDE GENERATING AND THE RNAI FUNGICIDE THEREOF
#1461ENGINEERED NODAVIRAL CARGO DELIVERY SYSTEMS
#1462RECOMBINANT VIRUS PRODUCTS AND METHODS FOR INHIBITION OF EXPRESSION OF DUX4
#1463GENE THERAPY FOR ANGELMAN SYNDROME
#1464MODULATION OF PREKALLIKREIN (PKK) EXPRESSION
#1465Antisense oligonucleotide targeting ATN1 mRNA or pre-mRNA
#1466ANTISENSE OLIGONUCLEOTIDES TARGETING ACTL6B
#1467MORPHOLINO OLIGOMERS FOR TREATMENT OF PERIPHERAL MYELIN PROTEIN 22 RELATED DISEASES
#1468VON WILLEBRAND FACTOR (VWF)-TARGETING AGENTS AND METHODS OF USING THE SAME
#1469MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES
#1470MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES
#1471Compositions and Methods for Silencing MYOC Expression
#1472Multi-Valent Oligonucleotide Agent and Methods of Use Thereof
#1473SENSE,SUPPRESSOR TRANSFER RNA COMPOSITIONS AND RELATED USES AND FUNCTIONS
#1474PRODUCTS AND METHODS FOR INHIBITION OF EXPRESSION OF PERIPHERAL MYELIN PROTEIN-22
#1475METHOD FOR PRODUCING DIRECTLY REPROGRAMMED NATURAL KILLER CELLS AND USES THEREOF
#1476COMPOSITIONS AND METHODS FOR ENHANCING THE THERAPEUTIC POTENTIAL OF STEM CELLS
#1477NEPHROTOXICITY REDUCING AGENT
#1478COMPOUNDS AND METHODS FOR INCREASING STMN2 EXPRESSION
#1479ANTI-FIBROSIS PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF
#1480DRUG DELIVERY SYSTEMS CONTAINING OXIDIZED CHOLESTEROLS
#1481Mirror Aptamer-Based Biosensors
#1482Selective Reduction of Allelic Variants
#1483TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1484COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
#1485METHODS AND COMPOSITIONS FOR SENSITIZATION OF TUMOR CELLS TO IMMUNE THERAPY
#1486SMALL INTERFERING RNA TARGETING APOC3 AND USES THEREOF
#1487CTLA-4 APTAMER CONJUGATES
#1488DOUBLE-STRANDED OLIGONUCLEOTIDE, COMPOSITION AND CONJUGATE CONTAINING DOUBLE-STRANDED OLIGONUCLEOTIDE, AND PREPARATION METHODS AND USES
#1489REDUCING INTRON RETENTION
#1490POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOF
#1491COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING STARGARDT'S DISEASE AND/OR RETINAL BINDING PROTEIN 4 (RBP4)-ASSOCIATED DISORDERS
#1492COMPOSITIONS FOR MODULATING ATAXIN 2 EXPRESSION
#1493SPECIFIC SYNTHETIC CHIMERIC XENONUCLEIC ACID GUIDE RNA; s(XNA-gRNA) FOR ENHANCING CRISPR MEDIATED GENOME EDITING EFFICIENCY
#1494STABILIZATION OF OLIGONUCLEOTIDE AND OLIGONUCLEOTIDE-PROTEIN COMPLEX USING ALKYLATED PHOSPHATE
#1495METHODS AND COMPOSITIONS TO DIAGNOSE AND TREAT TAUOPATHIES UTILIZING TRANSCRIPT VARIANTS OF PSEN2
#1496METABOLIC DISORDER-ASSOCIATED TARGET GENE IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1497OPTICAL TRANSMISSION SAMPLE HOLDER AND ANALYSIS, PARTICULARLY FOR HEMOGLOBIN
#1498TARGETED RNA EDITING BY LEVERAGING ENDOGENOUS ADAR USING ENGINEERED RNAS
#1499LIPID NANOPARTICLE SPHERICAL NUCLEIC ACIDS
#1500COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS